Article

Ankylosing Spondylitis Best Identified With Erosions on MRI

For patients who have ankylosing spondylitis (AS), radiographic assessment of the sacroiliac joint with MRI is the cornerstone of evaluation and treatment. Erosions alone-rather than bone marrow edema or contrast medium enhancement-are the most disease-specific measurable imaging findings in sacroiliac MRI of patients with AS in clinical practice.

For patients who have ankylosing spondylitis (AS), radiographic assessment of the sacroiliac joint with MRI is the cornerstone of evaluation and treatment. Erosions alone-rather than bone marrow edema or contrast medium enhancement-are the most disease-specific measurable imaging findings in sacroiliac MRI of patients with AS in clinical practice.

Wick and coworkers retrospectively reviewed laboratory data, clinical findings, and MRI scans from 179 patients who presented with sacroiliac pain. They attempted to determine whether any other findings might be more relevant for differentiating AS from other causes of sacroiliac pain.

Only 27 (15%) of the study participants unequivocally had AS. Everyone else had another condition, such as a degenerative disease, a rheumatologic disease, or a spondyloarthropathy. Of all the MRI findings, including bone cysts, bone marrow edema, and contrast medium enhancement, only erosions consistently and strongly identified AS. Patients with erosions who received a diagnosis of AS also had the highest C-reactive protein levels, although these elevated levels were nonspecific for AS.

The authors noted that rapid identification of patients with AS at early clinical disease stages, showing only discrete sacroiliac changes, provides an important window of treatment opportunity before irreversible damage occurs.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.